Lexicon Pharmaceuticals reported a net loss of $31.8 million ($0.07 per share) for the second quarter ended June 30, 2026, compared to net income of $3.3 million in the prior year period. Total revenues declined to $0.7 million from $28.9 million, driven by a drop in licensing revenue as no new milestones were recognized. The company secured a $100 million loan facility with Hercules Capital in May 2026, funding an initial $55 million tranche used to repay previous debt. Pipeline updates include the completion of enrollment for the Phase 3 SONATA-HCM study, with top-line data expected in Q1 2027, and ongoing NDA resubmission activities for ZYNQUISTA in type 1 diabetes targeting a Q4 2026 filing. Lexicon Pharmaceuticals is a biopharmaceutical company developing therapies for cardiometabolic disorders, neuropathic pain, and other conditions.